Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan O'Brien

Showing results (41-50 of 643) with videos related to

Pageof 65
Sort By:
Oncology (Williston Park, N.Y.)|August 31, 2011
Adverse prognostic features in chronic lymphocytic leukemiaSarah Schellhorn Mougalian, Susan O'Brien
Nature Reviews. Clinical Oncology|May 20, 2018
Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapyJan A Burger, Susan O'Brien
Blood|February 21, 2009
Insurance policies in the United States may explain part of the outcome differences of adolescents and young adults with acute lymphoblastic leukemia treated on adult versus pediatric regimensHagop M Kantarjian, Susan O'Brien
Expert Opinion on Drug Safety|June 20, 2017
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemiaPhu N Tran, Susan O'Brien
Leukemia & Lymphoma|March 5, 2003
Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemiaNina Shih Liu, Susan O'Brien
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Update on therapy of chronic lymphocytic leukemiaJohn G Gribben, Susan O'Brien
Clinical Advances in Hematology & Oncology : H&O|February 18, 2011
Maintenance therapy for B-chronic lymphocytic leukemiaSusan O'Brien, Neil E Kay
Nature|February 16, 2017
Cancer: A targeted treatment with off-target risksDavid A Fruman, Susan O'Brien
Mayo Clinic Proceedings|May 6, 2018
Chronic Lymphocytic Leukemia: Diagnosis and TreatmentPaolo Strati, Nitin Jain, Susan O'Brien
Cancer|November 6, 2003
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemiaFrancis Giles, Elihu Estey, Susan O'Brien
Pageof 65

Showing results (41-50 of 643) with videos related to

Sort By:
Pageof 65
Oncology (Williston Park, N.Y.)|August 31, 2011
Adverse prognostic features in chronic lymphocytic leukemiaSarah Schellhorn Mougalian, Susan O'Brien
Nature Reviews. Clinical Oncology|May 20, 2018
Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapyJan A Burger, Susan O'Brien
Blood|February 21, 2009
Insurance policies in the United States may explain part of the outcome differences of adolescents and young adults with acute lymphoblastic leukemia treated on adult versus pediatric regimensHagop M Kantarjian, Susan O'Brien
Expert Opinion on Drug Safety|June 20, 2017
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemiaPhu N Tran, Susan O'Brien
Leukemia & Lymphoma|March 5, 2003
Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemiaNina Shih Liu, Susan O'Brien
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Update on therapy of chronic lymphocytic leukemiaJohn G Gribben, Susan O'Brien
Clinical Advances in Hematology & Oncology : H&O|February 18, 2011
Maintenance therapy for B-chronic lymphocytic leukemiaSusan O'Brien, Neil E Kay
Nature|February 16, 2017
Cancer: A targeted treatment with off-target risksDavid A Fruman, Susan O'Brien
Mayo Clinic Proceedings|May 6, 2018
Chronic Lymphocytic Leukemia: Diagnosis and TreatmentPaolo Strati, Nitin Jain, Susan O'Brien
Cancer|November 6, 2003
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemiaFrancis Giles, Elihu Estey, Susan O'Brien
Pageof 65